XOMA Royalty (XOMA) Cash & Equivalents (2010 - 2026)
XOMA Royalty (XOMA) reported Cash & Equivalents of $85.6 million for Q1 2026, down 5.17% on a YoY basis from $90.3 million in Q1 2025, and up 3.25% sequentially from $82.9 million in Q4 2025.
XOMA Royalty (XOMA) Cash & Equivalents (2010 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 17 years of Cash & Equivalents data on file, last reported at $85.6 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Equivalents fell 5.17% year-over-year to $85.6 million; the trailing twelve-month figure through Mar 2026 stood at $85.6 million (down 5.17% YoY), and the FY2025 full-year result was $82.9 million, down 18.44% from the prior year.
- Cash & Equivalents grew to $85.6 million in Q1 2026, from $82.9 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $153.3 million in Q4 2023 to a low of $4.0 million in Q3 2024.
- A 5-year average of $79.1 million and a median of $84.4 million in 2022 frame the typical range for Cash & Equivalents.
- Peak annual rise in Cash & Equivalents reached 2457.29% in 2025, while the deepest fall reached 95.14% in 2025.
- Tracing XOMA's Cash & Equivalents over 5 years: stood at $78.3 million in 2022, then jumped by 95.81% to $153.3 million in 2023, then plunged by 33.69% to $101.7 million in 2024, then dropped by 18.44% to $82.9 million in 2025, then rose by 3.25% to $85.6 million in 2026.
- Business Quant data shows XOMA's Cash & Equivalents at $85.6 million in Q1 2026, $82.9 million in Q4 2025, and $102.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | 2.83 Mn |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - | 440.94 Mn |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 85.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 85.60 Mn |
| Dec 31, 2025 | 82.91 Mn |
| Sep 17, 2025 | 102.75 Mn |
| Jun 30, 2025 | 6.99 Mn |
| Mar 31, 2025 | 90.27 Mn |
| Dec 31, 2024 | 101.65 Mn |
| Sep 30, 2024 | 4.02 Mn |
| Jun 30, 2024 | 143.90 Mn |
| Mar 31, 2024 | 136.20 Mn |
| Dec 31, 2023 | 153.29 Mn |
| Sep 30, 2023 | 33.47 Mn |
| Jun 30, 2023 | 31.45 Mn |
| Mar 31, 2023 | 44.30 Mn |
| Sep 30, 2022 | 78.29 Mn |
| Jun 30, 2022 | 83.18 Mn |
| Mar 31, 2022 | 87.80 Mn |
| Dec 31, 2021 | 93.33 Mn |
| Sep 30, 2021 | 68.76 Mn |
| Jun 30, 2021 | 78.95 Mn |
| Mar 31, 2021 | 67.81 Mn |